Kexing Biopharm Partners with BioDlink to Embark on Latin American Markets

Article source：Kexing BiopharmOct 23,2025View： 2703

Recently, the first batch of orders for Kexing Biopharm (stock code: 688136.SH)'s bevacizumab biosimilar was successfully shipped to Colombia — licensed-in by BioDlink. This represents the product's first overseas commercialization shipment following marketing approval.

Bevacizumab is a commonly used drug in the oncology field, indicated worldwide for the treatment of various cancers. Having just received approval from Colombia's drug regulatory authority (INVIMA) not long ago, the rapid shipment just over two months later not only highlights the efficient international registration and supply capabilities of both partners but also brings new treatment options to local patients.

As an important pharmaceutical market in Latin America, Colombia boasts a well-established regulatory system and highly internationalized drug evaluation standards. Kexing Biopharm will use Colombia as a starting point to continuously advance the registration and commercialization of bevacizumab in the Latin American market.

Through this collaboration, leveraging BioDlink's high-standard production and quality systems, as well as Kexing Biopharm's professional expertise in international registrations and market promotion, the two parties will continue to join hands to drive the global layout of more high-quality drugs, providing more accessible treatment solutions for patients worldwide.